Skip to content
buyModerate

Thomas J. Schaefer bought $1,442 of RKDA

Chief Financial Officer at Arcadia Biosciences, Inc.. 700 shares at an average of $2.06, traded Feb 1, 2024, filed Feb 5, 2024.

Conviction score
50
Value
$1,442
700 shares
Holdings after
1,419
+97% from before
From 52-week low
+1%
low $2.39, close $2.42
From 52-week high
-82%
high $13.52, as of Feb 1, 2024

Score components

  • Role
    CFO
    +22
  • Trade size
    $1k at market
    0
  • Relative to holdings
    Holdings up 97%
    +10
  • Price context
    1% above the 52-week low; 82% below the 52-week high
    +18
  • Cluster
    No other insider buying within 14 days
    0
  • Repeat buying
    First buy in 90 days
    0
  • Track record
    Too few past buys to judge (1 with prices)
    0

What happened after comparable buys

Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.

This signal so far: 1m +5.0%, 3m -16.5%, 6m +8.8%.

Price around the trade, and since

From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.

RKDAOct 12, 2026 · close 0.23
Since filing Feb 5, 2024: -90.5%SPY +63.1% · excess -153.7%

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™

Rows in this filing

Every transaction in Form 4 0000950170-24-011271, as filed. Open on EDGAR

DateTransactionSharesPriceValueHoldings afterFiled
Feb 1, 2024POpen-market purchase
Common Stock
+700$2.06$1,4421,419Feb 5, 2024

Related signals

Other insiders at Arcadia Biosciences, Inc. and this insider’s other filings.

ScoreCompanyInsiderValueHoldingsFiled
39Weak
RKDAbuy 2
Arcadia Biosciences, Inc.
Thomas J. Schaefer
Chief Executive Officer
$1,743
700 shares
+33%
36Weak
RKDAbuy 2
Arcadia Biosciences, Inc.
Mark Kawakami
Chief Financial Officer
$1,743
700 shares
+35%
47Moderate
RKDAbuy 2
Arcadia Biosciences, Inc.
Thomas J. Schaefer
Chief Executive Officer
$1,442
700 shares
+49%
48Moderate
RKDAbuy 2
Arcadia Biosciences, Inc.
Mark Kawakami
Chief Financial Officer
$1,442
700 shares
+55%

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

Thomas J. Schaefer bought $1,442 of RKDA | InsiderTell